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Abstract 
Fifteen preterm infants suffering from respiratory distress syn-
drome were randomly allocated to receive either high-dose 
(200 mg/kg) or low-dose (100 mg/kg) surfactant treatment. Re-
treatments were done with the low dose. Blood pressure, blood 
gases and cerebral blood flow velocities were determined 
before and after 24 bolus instillations. With the high dose 
mean blood pressure and mean cerebral blood flow velocity 
dropped significantly. With the low dose only mean cerebral 
blood flow velocity decreased; the course was unrelated to 
blood pressure or PCO2 fluctuations. The mechanisms leading 
to the observed circulatory changes after surfactant instillation 
remain unclear. 
Introduction 
Controlled studies of surfactant substitu-
tion have impressively shown a reduction in 
mortality [1] and an even more pronounced 
decrease in the incidence of pneumothoraces 
in preterm infants with respiratory distress 
syndrome (RDS)[1]. 
RDS, its treatment and its complications 
are closely related to the occurrence of intra-
and periventricular hemorrhages (IVH). Sur-
factant treatment allows to ventilate babies at 
lower pressures [2], to avoid 'fighting the ven-
tilator' [3] and to reduce the incidence of air 
leaks. Since all these factors contribute to the 
pathogenesis of cerebral hemorrhage [4, 5], 
surfactant treatment should be expected to 
lower the incidence of this cerebral complica-
tion of RDS, too. However, it has been disap-
pointing to see that this expectation has net 
been fulfilled [1]. Some authors even reported 
an increased indicence of I V H after surfactar t 
substitution [6, 7]. 
Recent studies of systemic and cerebri I 
hemodynamics after surfactant bolus instilla-
tion showed increases as well as decreases i 1 
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ar erial blood pressure (BP) [8-10]. Van Bel et 
a l [11] found a fluctuating pattern of cerebral 
blood flow velocities (CBFVs). 
We investigated the effects of two different 
doses of a natural surfactant preparation on 
BP and CBFVs in premature infants with 
RDS to find out whether a lower surfactant 
dose causes less circulatory disturbances. 
Patients and Methods 
Between August 1990 and December 1991, our 
department participated in a randomized controlled 
multicenter trial on surfactant substitution ('Curosurf 
4') [20] with the aim to evaluate two different dose reg-
imens for the porcine surfactant preparation Curosurf 
[12-14]. The study protocol was approved by the local 
Ethics Committee. 
Infants were eligible for 'Curosurf 4' if R D S was 
diagnosed clinically and radiologically, if the arterial/ 
alveolar oxygen tension ratio was 0.22 or less, i f they 
were less than 72 h of age, and if written parental con-
sent had been obtained. 
Fifteen infants were monitored for their circulatory 
reactions to surfactant bolus instillations after they had 
been randomly allocated to receive either high-dose 
(200 mg/kg body weight initially plus up to 4 doses of 
100 mg/kg each after intervals of 12 h) or low-dose 
(100 mg/kg body weight initially plus up to 2 doses of 
100 mg/kg each after 12 and 24 h) Curosurf treatment. 
Each dose was divided into two parts and instilled as 
described previously [13], with the infant's head 
turned on either side during instillation but returned to 
the midline immediately thereafter to avoid jugular 
venous occlusion. In total, 24 instillations were evalu-
ated. 
In these infants, CBFVs were measured by Doppler 
sonography carried out by one of two investigators 
(M.R., H.S.). A pulsed-Doppler, two-dimensional ul-
trasound scanner (Sonoline SL 2, Siemens, Erlangen, 
Germany) with a 7.5-MHz Doppler probe was used to 
measure CBFVs. This was done in the right internal 
carotid artery immediately beneath the lateral edge of 
the sella turcica. Doppler frequencies were recorded 
when the sharpest characteristic visual and highest 
audible signals were obtained [ 15]. A tracing of at least 
six equal heart cycles was printed out. Peak systolic 
and end-diastolic CBFVs could be read after internal 
computing of the Doppler frequencies; mean C B F V 
vas determined by calculating the area under the 
I oppler curve according to Jorch [ 16]. As most infants 
did not have arterial catheters, systolic, mean, and dia-
stolic arterial BPs were measured oscillometrically (Di-
namap, Criticon Inc., Fla., USA). A l l measurements 
were performed in the supine position. 
Data on CBFVs, BP, transcutaneous oxygen and 
carbon dioxide tensions (tcP0 2 and tcPC0 2 ) were 
obtained before and 2, 5, 10, 15, 20, 30 and 60min 
after surfactant instillation. T c P 0 2 and tcPC0 2 were 
verified by arterial blood sampling. 
The Mann-Whitney U test was applied to evaluate 
differences between variables of the two groups treated 
with different doses of surfactant. For all repeated 
measurements, a two-factor analysis of variance was 
carried out, the factors being time and dose. A p < 0.05 
was considered statistically significant. Al l calculations 
were done with the SPSS-PC+ statistical package 
(SPSS Inc., Chicago, 111., USA). 
Results 
Of the 15 infants studied, median birth 
weight was 1,060 g (range 670-1,770 g), and 
median gestational age 29 weeks (24-31). 
Nine of them were boys. Seven of them had 
grade 3 or 4 RDS as judged by chest X-ray. 
Median FiC>2 before the first surfactant sub-
stitution was 0.80 (0.50-1.0). 
Eleven initial high-dose instillations were 
evaluated and compared to 13 low-dose instil-
lations which were either given initially or as 
retreatments. The age at surfactant instilla-
tions was not significantly different for the 
high-dose group as compared to the low-dose 
group (9h, 3-67, vs. 17 h, 3-37; p = 0.32). 
FiC>2 decreased significantly with both regi-
mens, but the effect of the high dose was more 
pronounced (fig. la). Accordingly, in 7 of 11 
infants who received a high dose, the addition-
al oxygen requirement was reduced by 50% or 
more within 1 h whereas only 1 of 13 patients 
showed such a response after a low dose (p < 
0.05). After surfactant instillation, tcPC0 2 in-
creased transiently (fig. lb) without a signifi-
cant difference between high and low dose. 
Systolic and mean arterial blood pressure 
dropped significantly after instillation of a 
1.00-1 
Fig. 1, Courses of FiC>2 (a) and 
PCO2 (b) before and after different 
doses of surfactant. Mean ± S E M . 
• = Instillation of 200 mg/kg (n = 
11); O = instillation of 100 mg/kg 
(n = 13). The F i 0 2 courses are sig-
nificantly different (p < 0.01) by 
two-factor analysis of variance 
(dose, time). The courses of P C 0 2 
do not differ significnatly between 
the two doses; the increase after 
surfactant instillation is statistical-
ly significant (p < 0.01). 
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high dose. The lowest values occurred after 
2 min; they recovered within 5 min. Following 
the lower dose of surfactant, BP showed no 
significant change (fig. 2). The mean CBFV in 
the right internal carotid artery decreased sig-
nificantly after surfactant instillation with 
both dosing regimens (fig. 3a). Although the 
curves seem to be different, analysis of vari-
ance revealed that they go parallel with pre-
treatment values which are slightly but not sig-
nificantly different (p = 0.13). End-diastolic 
CBFV decreased more dramatically: the val-
ues after surfactant instillation were signifi-
cantly different from the pretreatment values 
between 5 and 30 min (fig. 3b). Again, the dif-
ferences between the two groups depicted in 
figure 3 were not statistically relevant. 
End-diastolic CBFV was zero or negative 
after 10 of 11 high-dose instillations and after 
7 of 13 low-dose instillations (Fisher's exact 
test, p = 0.12). 
The grade of improvement within 1 h after 
surfactant treatment (as judged by the de-
crease in oxygen requirement within this 
time, i.e. FiC>2 before surfactant substitution 
minus FiC>2 1 h thereafter) was not statistical-
ly related to the grade of the decrease in 
CBFVs (CBFV before surfactant substitution 
minus C B F V 2 or 5 min thereafter, respec-
tively). This was true for mean C B F V as well 
as for end-diastolic CBFVs (data not shown). 
Discussion 
CBFVs in preterm infants are influenced 
by various factors such as birth weight, gest • 
tional age, postnatal age, persistent duett s 
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Fig. 2. Mean arterial blood 
pressure before and after different 
doses of surfactant. After the high 
dose(#, n = 11, mean ± SEM), the 
initial value after surfactant instil-
lation was significantly different 
from the pretreatment values (* p < 
0.05). 
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Fig. 3. Mean (a) and end-dia-
stolic (b) CBFVs after different 
doses of surfactant. For both pa-
rameters, the pretreatment values 
were not significantly different be-
tween the two groups. After surfac-
tant instillation, both mean and 
end-diastolic CBFVs dropped sig-
nificantly in both groups as com-
pared to the pretreatment values 
(p < 0.01), but were not different 
between the two groups (p = 0.77 
for mean, p = 0.72 for end-diastolic 
CBFVs; two-factor analysis of vari-
ance). 
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arteriosus, intracranial abnormalities, and 
drug administration [17]. For the tracheal in-
stillation of surfactant, transient changes in 
CBFVs have been described [9]. 
Similar to these investigators, we were in-
terested in circulatory changes after surfac-
tant instillation in very premature infants 
who represent the group of neonates with the 
most urgent need for surfactant treatment [3]. 
Our observations closely resemble those of 
Cowan et al. [9]: With the high Curosurf dose, 
a transient but significant decrease in arterial 
BP occurred. Similarly, the short-term eleva-
tion of tcPCC>2 is consistent with the observa-
tions made by Cowan et al. [9]. They also 
found a significant reduction in the mean 
CBFV in the middle cerebral artery after sur-
factant instillation, which lasted for about 
20 min. In our patients, this decrease in the 
mean CBFV was shorter, yet a more sustained 
decrease could be observed for end-diastolic 
CBFV. 
Although there was no significant fall in 
BP after the low surfactant dose in the present 
study, still a significant decrease in mean and 
end-diastolic CBFVs could be measured, 
which was not significantly different from the 
changes observed after high doses. (Only the 
recovery of the end-diastolic C B F V took more 
time after high-dose instillations.) 
This observation is puzzling to us for the 
following reasons: We expected CBFV 
changes to go parallel with BP variations as in 
preterm infants cerebral perfusion is pressure-
passive [5, 18]. We conclude that the altera-
tions of CBFVs observed after surfactant bo-
lus instillation do not depend on alterations of 
arterial BP. 
We also anticipated that a more pro-
nounced circulatory effect would occur with a 
rapid pulmonary response after surfactant 
treatment [19] when compared to a poor re-
sponse. Most of the patients receiving a low 
dose revealed, in terms of oxygenation, such 
a poor short-term response. Nevertheless, 
changes in C B F V occurred in spite of a 'poor 
response' of oxygenation. 
There is no easy explanation for these cir-
culatory changes after surfactant treatment, 
neither for BP nor for C B F V alterations. The 
decrease in BP may be related to the rapid 
recruitment of atelectatic areas by surfactant 
treatment [21, 22], possibly leading to a de-
crease in the pulmonary vascular resistance 
and, consequently, to an increase in left-to-
right shunting through the ductus arteriosus 
[11]. Also a decrease in peripheral vascular 
resistance as described by Skov et al. [10] and 
by Cowan et al. [9] may lead to a transient 
drop in BP. CBFVs may also be subject to 
variations in PCO2. In the present study, how-
ever, the transient increase in PCO2 after sur-
factant instillation should have caused an in-
crease in CBFVs [17] but not a decrease as 
observed. 
The alterations of CBFVs as observed by 
Cowan et al. [9] and in this study do not 
resemble the 'fluctuating pattern' of cerebral 
blood flow that has been described by van Bel 
et al. [11] and that has to be regarded as a 
high-risk factor for cerebral hemorrhages [ 15]. 
However, the results of Lohrer et al. [23] sug-
gest that a drop in CBFVs after surfactant 
therapy is associated with an increased risk of 
cerebral hemorrhage. 
Although each neonatologist tries to avoid 
abrupt changes in a preterm infant's condi-
tion and dislikes any interventions that cause 
sudden changes in BP or CBFVs, it should be 
emphasized that up to now there is no evi-
dence that surfactant treatment actually 
causes cerebral bleedings. Nevertheless, it 
seems desirable to avoid abrupt CBFV 
changes, e.g. by modified instillation tech-
niques. It is important to document that sue) 
modifications preserve the beneficial effect' 
of surfactant substitution while avoiding cir 
culatory disturbances. 
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